 SOUTH SAN FRANCISCO, Calif., April 13, 2021 PRNewswire -- Rigel Pharmaceuticals, Inc. Nasdaq: RIGL, today announced positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase SYK inhibitor, for the treatment of hospitalized patients with COVID-19. 